Quantum Genomics - Expecting an eventful 2021
Quantum Genomics is expecting two very key pieces of data for firibastat in 2021. First up will be top-line data from the Phase IIb QUORUM study in 294 heart failure patients, which is expected to read out by the end of Q221. Then data from the pivotal Phase III FRESH study in 500 difficult-to-treat or resistant hypertension patients is expected by the end of the year. If positive, these data should help open the door for partnerships with major pharmaceutical companies in the lucrative US and EU markets.Quantum Gernomics is a biotechnology firm specializing in the development of innovative drugs to combat cardiovascular diseases. Run by professionals in creating and managing technological start-ups and drug development, as well as researchers and inventors, Co. has established contractual relations with institutions of academic excellence in France (Inserm, CollA
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.